New therapeutic agents for glycemic control in diabetes mellitus
Article information
J Korean Med Assoc. 2012;55(3):271-278
Publication date (electronic) : 2012 March 09
doi :
https://doi.org/10.5124/jkma.2012.55.3.271
Received 2012 February 17; Accepted 2012 February 30.
Abstract
A recent report from International Diabetes Federation estimates that 366 million people have diabetes in 2011 and this will have risen to 552 million by 2030. That means one adult in 10 will have diabetes. The prevalence of diabetes among Korean adults aged 20 to 79 years in 2010 was estimated at 9.4% (3.3 million). Diabetes mellitus has thus become a social and economic burden in Korea. However, the percentage of patients to reach their target goal for glycemic control (hemoglobin A1c <7%) is only 40.3%. That indicates further effort for management of diabetic patients is needed. Current diabetic medication includes sulfonylurea, metformin, α-glucosidase inhibitor, thiazolidinedione and dipeptidyl peptidase-4 inhibitor as well as insulin. In this review article, we examine the clinical effects upcoming new diabetes medications and their differences from previous medications.
Keywords: Diabetes mellitus; Therapeutics; Hyperglycemia
References
1. International Diabetes Federation. IDF diabetes atlas 2011. 5th edth ed. Brussels: International Diabetes Federation; 143.
2. Kim DJ. The epidemiology of diabetes in Korea. Diabetes Metab J 2011. 35303–308.
3. Korean Diabetes Association. Korean Diabetes Association Task Force Team for basic statistical study of Korean diabetes mellitus: diabetes in Korea 2007 2007. Seoul: Korean Diabetes Association;
4. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care 2011. 34Suppl 2. S279–S284.
5. Steensgaard DB, Thomsen JK, Olsen HB, Knudsen LB. The molecular basis for the delayed absorption of the once-daily human GLP-1 analogue, liraglutide. Diabetes 2008. 57Suppl 1. A164.
6. Krause A, Kirwin J. Exenatide LAR: a sustained-release formulation of exenatide for the treatment of type 2 diabetes. Formulary 2010. 4543–51.
7. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011. 137–18.
8. Zinman B, Fulcher G, Rao PV, Thomas N, Endahl LA, Johansen T, Lindh R, Lewin A, Rosenstock J, Pinget M, Mathieu C. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet 2011. 377924–931.
9. Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA, Lyby K, Jendle JH, Roberts AP, DeVries JH, Meneghini LF. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011. 34661–665.
10. Simon AC, DeVries JH. The future of basal insulin supplementation. Diabetes Technol Ther 2011. 13Suppl 1. S103–S108.
11. Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract 2008. 14782–790.
12. White JR. Apple trees to sodium glucose co-transporter inhibitors: a review of SGLT2 inhibition. Clin Diabetes 2010. 285–10.
13. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009. 32650–657.
14. Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010. 70377–385.
15. Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010. 9534–42.
16. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 2008. 1681975–1983.
17. Israili ZH. Advances in the treatment of type 2 diabetes mellitus. Am J Ther 2011. 18117–152.
18. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009. 15540–559.
19. Standards of medical care in diabetes: 2012. Diabetes Care 2012. 35Suppl 1. S11–S63.
20. Holt RI, Barnett AH, Bailey CJ. Bromocriptine: old drug, new formulation and new indication. Diabetes Obes Metab 2010. 121048–1057.
21. Musil BA, Walbrandt Pigarelli DL. New drugs for glycemic control in type 2 diabetes mellitus. J Pharm Soc Wis 2010. 516–25.
22. Wilding JP, Gause-Nilsson I, Persson A. GALLANT 7 Study Group. Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes. Diab Vasc Dis Res 2007. 4194–203.
23. Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther 2005. 271181–1195.
24. Cariou B, Zair Y, Staels B, Bruckert E. Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 2011. 342008–2014.
Article information Continued
Copyright © 2012 Korean Medical Association
